Five out of seven mice treated with CD19-BBz CAR-NK cells became tumor-free for at least 46 days after treatment, which resulted in significantly improved survival compared to non-modified NK cell or 18.2-BBz CAR-NK treatment (Fig. 1d–f). This evidence concerns the gene CD19 and neoplasm.